As Chief Executive Officer of Diaceutics, Peter has driven the organization from its inception in 2005 to become a leader in innovative solutions that enable pharma to leverage diagnostic testing globally. He has overseen the expansion and development of Diaceutics to support pharma therapy and diagnostic commercialization via a worldwide team.

Peter recognized early on that precision medicine would be an increasingly large part of the drug development paradigm, representing a shift in how the pharmaceutical industry operates. Today, he is a thought leader in precision medicine commercialization and Diaceutics provides the top 20 precision medicine pharma companies with the data, analytics and global lab implementation services required to align biomarker and diagnostic demand with therapy, patient and revenue targets in key markets.